secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0000078003-24-000144
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer extends vesting and performance periods on 2022/2023 long-term equity awards for ~9,000 employees
--------------------------------------------------------------------------------

- Up to 9,000 active employees eligible, including CEO Bourla, CFO Denton, and other named executives.
- 2022 and 2023 TSRUs can be extended for 2 years: settlement now Feb 2029 (2022 grants) and Feb 2030 (2023 grants).
- 2022 and 2023 PSAs can get a 2-year performance period extension, vesting in 2027 and 2028 respectively.
- Modifications aim to restore retention value after COVID-related stock price decline reduced award incentive.
- Election is voluntary via a forthcoming tender offer; all other award terms remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000144/0000078003-24-000144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000144/pfe-20240724.htm
  HTML page:      https://secwatch.observer/filing/0000078003-24-000144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer